Radiolabeled imaging agents for Alzheimer's disease  

作　　者：Jiajun Wu Kexin Li Jie Yang Meiting Mao Yan Cheng 

机构地区：[1]Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry,Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology,West China School of Pharmacy,Sichuan University,Chengdu,Sichuan province,China

出　　处：《iRADIOLOGY》2024年第1期80-95,共16页融合影像学(英文)

基　　金：The Fundamental Research Funds for the Central Universities,and the Higher Education Discipline Innovation Project,Grant/Award Number:B18035;National Natural Science Foundation of Sichuan Province of China,Grant/Award Number:2023NSFSC1721。

摘　　要：Alzheimer's disease(AD)is a chronic and progressive neurodegenerative disorder with long preclinical and prodromal phases in older people.Molecular imaging is a promising approach for noninvasive in vivo identification and tracking pathophysiological changes.In particular,nuclear neuroimaging in AD has extended beyond traditional evaluation of brain perfusion and glucose metabolism,and has achieved substantial progress over the past 2 decades.To gain a comprehensive understanding of nuclear neuroimaging with different targets in the brain,this review provides an overview of the literature on the current status and recent progress of the development of radioligands for definitive and differential diagnosis of AD.

关 键 词：Alzheimer's disease(AD) β-amyloid(Aβ) molecular probe NEUROINFLAMMATION positron emission tomography(PET) TAU 

分 类 号：R74[医药卫生—神经病学与精神病学]